Zurück
die discussion ganz interessant:
www.captodayonline.com/...TY%20%20EPIGENOMICS%20N%20Helden%20|%20wallstreet-online.de%20-%20Vollständige%20Diskussion%20unter:%20www.wallstreet-online.de/diskussion/...0/epigenomics-n-helden
Discussion. These results are not unexpected since adenomatous polyps are frequently found in patients with a positive methylated SEPT9 test who do not have cancer.3,4 The results are also consistent with the large body of data supporting the significant difference in prevalence between adenomas and cancer across all screening-age-eligible groups.5,6 As the detection and removal of precancerous lesions prevents CRC,7,8 the referral of this patient for a diagnostic colonoscopy achieved the desired medical outcome.
The intended use of methylated SEPT9, under the FDA approval, is for those patients who have been offered other screening options (as per U.S. Preventive Services Task Force, 2008 guidelines) and have refused these forms of colorectal cancer screening. This patient decided to have the blood test based on the unremarkable results of two previous colonoscopies as well as interest in a novel molecular diagnostic technology. As it turned out, the positive methylated SEPT9 result prompted the patient to quickly undergo a colonoscopy.
This colon cancer screening test involves a simple blood draw and serves the purpose of bringing unscreened patients to the gold standard of screening, which remains colonoscopy and histopathology. The intended use of the product is for those one of three adults in the United States who refuse all forms of colon cancer screening. It is known from clinical trials that even those who repeatedly refused colon cancer screening will go on to colonoscopy with a positive blood test result, and 99.5 percent of otherwise noncompliant patients will have their blood drawn for this test.9 Since the patient experience is a simple blood draw, this molecular diagnostic test holds great promise as a key to bringing the unscreened in for screening and medical care to prevent deaths from advanced colon cancer.
www.captodayonline.com/...TY%20%20EPIGENOMICS%20N%20Helden%20|%20wallstreet-online.de%20-%20Vollständige%20Diskussion%20unter:%20www.wallstreet-online.de/diskussion/...0/epigenomics-n-helden
Discussion. These results are not unexpected since adenomatous polyps are frequently found in patients with a positive methylated SEPT9 test who do not have cancer.3,4 The results are also consistent with the large body of data supporting the significant difference in prevalence between adenomas and cancer across all screening-age-eligible groups.5,6 As the detection and removal of precancerous lesions prevents CRC,7,8 the referral of this patient for a diagnostic colonoscopy achieved the desired medical outcome.
The intended use of methylated SEPT9, under the FDA approval, is for those patients who have been offered other screening options (as per U.S. Preventive Services Task Force, 2008 guidelines) and have refused these forms of colorectal cancer screening. This patient decided to have the blood test based on the unremarkable results of two previous colonoscopies as well as interest in a novel molecular diagnostic technology. As it turned out, the positive methylated SEPT9 result prompted the patient to quickly undergo a colonoscopy.
This colon cancer screening test involves a simple blood draw and serves the purpose of bringing unscreened patients to the gold standard of screening, which remains colonoscopy and histopathology. The intended use of the product is for those one of three adults in the United States who refuse all forms of colon cancer screening. It is known from clinical trials that even those who repeatedly refused colon cancer screening will go on to colonoscopy with a positive blood test result, and 99.5 percent of otherwise noncompliant patients will have their blood drawn for this test.9 Since the patient experience is a simple blood draw, this molecular diagnostic test holds great promise as a key to bringing the unscreened in for screening and medical care to prevent deaths from advanced colon cancer.
